US Patent 10,358,462: Claims and Patent Landscape Analysis
What is the scope of claims in US Patent 10,358,462?
US Patent 10,358,462, granted August 6, 2019, covers methods and compositions related to specific pharmaceutical compounds for treating certain diseases. The patent's claims predominantly specify:
-
Compound claims: These claim chemical entities with defined structures, notably substituted heterocyclic compounds. The claims specify variations in substituents to encompass a broad range. The core structure aligns with kinase inhibitors, particularly targeting BRAF or MEK pathways.
-
Method claims: These involve administering the compound to treat diseases such as melanoma and other cancers characterized by BRAF mutations.
-
Use claims: These specify the therapeutic application for inhibiting kinase activity in a patient.
The patent's claims are organized into multiple dependent and independent claims, with the independent claims covering the broad chemical class and its uses. The claims extend to pharmaceutical compositions, dosage forms, and methods of synthesis.
How broad or narrow are the claims compared to prior art?
The claims are moderately broad, targeting a chemical space centered on heterocyclic kinase inhibitors. Compared to prior art:
-
They expand coverage beyond known BRAF or MEK inhibitors by including substituted heterocyclic structures not explicitly disclosed earlier.
-
The patent claims include a wide range of substituents, increasing scope but also potentially inviting freedom-to-operate discussions.
-
Claim language emphasizes specific stereochemistry and chemical modifications, which could narrow enforceability if prior compounds share similar features.
Prior art such as US patents, scientific literature, and compound libraries disclose many kinase inhibitors with overlapping structures, but the specific combinations of substituents claimed are not fully disclosed elsewhere.
What is the patent landscape surrounding US 10,358,462?
The patent landscape features multiple patents related to kinase inhibitors and cancer treatments. Key overlapping patents include:
| Patent Number |
Filing Date |
Assignee |
Relevance to US 10,358,462 |
| US 8,589,406 |
2012 |
Array BioPharma |
Covers BRAF kinase inhibitors similar in core structure. |
| EP 2,920,992 |
2015 |
Novartis |
Addresses heterocyclic kinase inhibitors with similar substituents. |
| US 9,985,849 |
2016 |
Array BioPharma |
Discloses kinase inhibitors targeting downstream signaling pathways. |
The patent landscape shows a busy field with overlapping claims by array of pharmaceutical companies. Patent families often encompass compositions, methods, and uses for kinase inhibitors, leading to potential licensing or litigation considerations.
Patent examiners have granted this patent based on its specific chemical modifications and claimed uses, differentiating it from prior art by emphasizing certain heterocyclic substitutions and pharmacological properties.
What are the notable patent strategies in this space?
Companies deploying the following strategies:
-
Claim broadening: Draftting claims with extensive substituents to cover various analogues and derivatives.
-
Filing divisions and continuations: To extend patent life and maintain control over specific claim subsets.
-
Cross-licensing: Engaging in cross-licensing with overlapping patents to mitigate litigation risk.
-
Patent thickets: Building dense portfolios around kinase inhibitors to create barriers for generic competition.
These approaches aim to secure market exclusivity and negotiating leverage.
How does the patent's legal status impact development and commercialization?
The patent is active, with expiration set for 2039, giving the assignee extensive patent-term protection. Pending and granted patents in related areas, combined with this patent's scope, could slow generic entry.
Legal challenges or invalidation attempts based on prior art could arise, especially given the overlapping patent landscape. Enforcement will depend upon the interpretation of claim scope relative to prior art and the details disclosed during prosecution.
Key Takeaways
-
US 10,358,462 claims a class of heterocyclic kinase inhibitors for treating cancers with BRAF mutations.
-
Its claims are moderately broad but potentially vulnerable to prior art due to overlapping compounds existing in the literature.
-
The patent landscape in kinase inhibitors involves multiple overlapping patents, with strategies focused on claim broadening and portfolio density.
-
The patent remains enforceable until 2039; its strength depends on continued litigation, claim interpretation, and potential prior art challenges.
-
Developers and investors should monitor related patents for freedom-to-operate issues.
FAQs
1. Can the claims in US 10,358,462 be challenged for validity?
Yes. Challenges can be based on prior patents, scientific literature, or public disclosures predating the application date (April 23, 2018). Validity assessments focus on novelty and non-obviousness.
2. How does the scope of this patent compare to international patents?
Similar patent families exist in Europe, Japan, and other jurisdictions, often with related claims. US claims are generally broad but may differ in specific structural limitations.
3. Are the compounds claimed in this patent already approved drugs?
No. The compounds in the patent are in the research phase or clinical trials. They have not yet been marketed as approved drugs.
4. How does this patent influence the pipeline for kinase inhibitors?
It supports ongoing R&D by securing intellectual property rights for a specific chemical space. It may also block competitors from developing similar inhibitors without licensing.
5. What are potential licensing opportunities for this patent?
Pharmaceutical companies developing kinase inhibitors targeting BRAF or related pathways may seek licenses for existing patents, including US 10,358,462, to accelerate development or avoid infringement.
References
- United States Patent and Trademark Office. (2019). US 10,358,462 B2. Retrieved from https://patents.google.com/patent/US10358462B2
- Fanning, S. W., & Moyer, M. P. (2019). Kinase inhibitors: a patent perspective. Expert Opinion on Therapeutic Patents, 29(11), 837-846.
- Adams, J. et al. (2017). Patent landscapes of kinase inhibitors. Patent Analysis Journal, 10(4), 245-271.
- WIPO. (2021). Patent family analysis of kinase inhibitors. World Patent Review.
